Your search returned 813 results.

Results
	801.	Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. [electronic resource] by van Acker, S A Boven, E Kuiper, K van den Berg, D J Grimbergen, J A Kramer, K Bast, A van der Vijgh, W J Producer: 19990325 In: Clinical cancer research : an official journal of the American Association for Cancer Research vol. 3 Availability: No items available. Save to lists Add to cart (remove)
	802.	Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. [electronic resource] by Lipshultz, Steven E Scully, Rebecca E Lipsitz, Stuart R Sallan, Stephen E Silverman, Lewis B Miller, Tracie L Barry, Elly V Asselin, Barbara L Athale, Uma Clavell, Luis A Larsen, Eric Moghrabi, Albert Samson, Yvan Michon, Bruno Schorin, Marshall A Cohen, Harvey J Neuberg, Donna S Orav, E John Colan, Steven D Producer: 20101101 In: The Lancet. Oncology vol. 11 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	803.	Can anthracycline therapy for pediatric malignancies be less cardiotoxic? [electronic resource] by Fulbright, Joy M Huh, Winston Anderson, Pete Chandra, Joya Producer: 20110214 In: Current oncology reports vol. 12 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	804.	The antitumor triazoloacridone C-1305 is a topoisomerase II poison with unusual properties. [electronic resource] by Lemke, Krzysztof Poindessous, Virginie Skladanowski, Andrzej Larsen, Annette K Producer: 20041126 In: Molecular pharmacology vol. 66 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	805.	Oxidant-induced iron signaling in Doxorubicin-mediated apoptosis. [electronic resource] by Kotamraju, Srigiridhar Kalivendi, Shasi V Konorev, Eugene Chitambar, Christopher R Joseph, Joy Kalyanaraman, B Producer: 20040415 In: Methods in enzymology vol. 378 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	806.	Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model. [electronic resource] by Xiang, Ping Deng, Hai Yan Li, Karen Huang, Guo-Ying Chen, Yuan Tu, Liu Ng, Pak Cheung Pong, Nga Hin Zhao, Hailu Zhang, Lei Sung, Rita Yn Tz Producer: 20081222 In: Cancer chemotherapy and pharmacology vol. 63 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	807.	Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib. [electronic resource] by Hasinoff, Brian B Patel, Daywin Producer: 20100503 In: Cardiovascular toxicology vol. 10 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	808.	Topoisomerase II inhibitor-induced apoptosis in thymocytes and lymphoma cells. [electronic resource] by Kizaki, H Onishi, Y Producer: 19971110 In: Advances in enzyme regulation vol. 37 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	809.	A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors. [electronic resource] by Liang, Hong Wu, Xing Yalowich, Jack C Hasinoff, Brian B Producer: 20080407 In: Molecular pharmacology vol. 73 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	810.	A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. [electronic resource] by Braybrooke, J P O'Byrne, K J Propper, D J Blann, A Saunders, M Dobbs, N Han, C Woodhull, J Mitchell, K Crew, J Smith, K Stephens, R Ganesan, T S Talbot, D C Harris, A L Producer: 20010419 In: Clinical cancer research : an official journal of the American Association for Cancer Research vol. 6 Availability: No items available. Save to lists Add to cart (remove)
	811.	The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukemia. [electronic resource] by Niitsu, Nozomi Higashihara, Masaaki Honma, Yoshio Producer: 20021212 In: Experimental hematology vol. 30 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	812.	Cardiotoxicity in patients treated with bevacizumab is potentially reversible. [electronic resource] by Hawkes, Eliza A Okines, Alicia F C Plummer, Chris Cunningham, David Producer: 20110823 In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 29 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	813.	Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform. [electronic resource] by Wessel, I Jensen, L H Jensen, P B Falck, J Rose, A Roerth, M Nitiss, J L Sehested, M Producer: 19990812 In: Cancer research vol. 59 Availability: No items available. Save to lists Add to cart (remove)

First
Previous
32
33
34
35
36
37
38
39
40
41